OrbiMed is a global healthcare investment firm focused on supporting the development of therapies, medical devices, diagnostics, and health IT. Established in 1989, it manages a broad investment platform across venture capital, private equity, and public equity, targeting opportunities from early-stage startups to mature companies. The firm backs companies across biopharmaceuticals, biotechnology, life sciences, and digital health, providing financing and strategic resources to accelerate innovation. With a multinational presence and offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, and beyond, OrbiMed pursues a diversified portfolio of healthcare companies worldwide.

RA Capital Management is a Boston-based investment firm that pursues evidence-based investing across public and private healthcare, life sciences, and planetary health sectors. The firm supports the growth of innovative companies from seed to later-stage financings, focusing on drugs, medical devices, diagnostics, biotech services, and research tools. RA Capital combines a data-driven research platform, TechAtlas, with a collaborative investment approach and a healthcare incubator, Raven, to help management teams advance ideas from inception through development and commercialization. It frequently co-invests, takes board seats, and participates in follow-on financings, aiming to back ventures that improve patient outcomes and reduce costs. The firm emphasizes US and European opportunities, maintains a multi-stage investment scope, and is headquartered in Boston.

SOSV is a global venture capital firm focused on deep tech investments that address human and planetary health, backing seed-to-growth startups and delivering hands-on programs that accelerate product development, customer acquisition, and fundraising. It operates accelerator-like facilities for deep tech founders, including IndieBio in San Francisco and New York (referred to as SOSV SF & NY) and HAX in Newark, offering labs, offices, engineering support, mentorship, and broad access to an investor network. With a large and active portfolio across dozens of countries, SOSV supports hundreds of pre-seed and follow-on investments annually from its New Jersey base and through its global network, emphasizing long-term founder support beyond initial funding and fostering collaboration among portfolio companies and investors.

The European Innovation Council is a European Commission initiative that supports Europe’s deep-tech innovators, researchers, and startups. It funds breakthrough research and technology transfer projects, and delivers equity-like investments through the EIC Fund, as well as prizes and acceleration services to help teams scale. The council also co-invests with private investors in early-stage ventures and places emphasis on high-impact technologies with ESG relevance. Established in 2018 and headquartered in Brussels, it concentrates on deep-tech sectors including defence and dual-use technologies, while promoting international collaboration and market access for awardees. It aims to strengthen Europe’s innovation ecosystem by sharing data, hosting events, publishing insights, and fostering partnerships that accelerate the journey from lab to market.

General Catalyst is a venture capital firm founded in 2000 and headquartered in Cambridge, Massachusetts, with additional offices in North America and Europe. The firm backs companies from seed to growth stages and invests across technology sectors, including software, consumer and enterprise tech, fintech, crypto, healthcare, and AI-related ventures. General Catalyst provides not only capital but strategic guidance to help portfolio companies scale and innovate. Over the years it has managed multiple funds and built a global portfolio of technology businesses, aiming to support resilient growth and transformative technologies.

Morningside is a venture capital firm based in the greater Boston area, founded in 1986 as a family office for the Chan family. It makes investments in companies developing novel science and technology across life sciences, digital health, artificial intelligence, materials and general technology, with a long-term, values-driven approach and a focus on ethical company-building. The team comprises investment professionals with deep sector experience, and the firm maintains charitable commitments to education, research and healthcare, supporting institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School and the MIT Morningside Academy for Design.

Alumni Ventures is a venture capital firm headquartered in Manchester, New Hampshire, that expands access to venture investing for accredited individuals by co-investing with leading venture capital firms and enabling participation through various structures such as funds, syndicates, and investment clubs. It collaborates with top firms including Andreessen Horowitz, Sequoia, and Y Combinator and supports opportunities across pre-seed to growth stages, across multiple sectors and geographies. The firm emphasizes rigorous due diligence, transparency, and diversification, leveraging a broad network of alumni investors and partners to connect founders with strategic capital and resources. With a global footprint and active involvement in the venture ecosystem, Alumni Ventures aims to broaden participation in venture capital while maintaining disciplined, founder-friendly investing.

Invus is a global investment firm founded in 1985 that builds lasting value by partnering with management teams to transform industries. It employs a flexible, long-term approach, aligning incentives with entrepreneurs and investors, and providing capital and strategic guidance to support growth through cycles. The firm invests directly in companies and makes selective co-investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, and education. With a patient mindset and emphasis on backing owner-managers, Invus seeks opportunities where its involvement adds strategic value beyond capital. It maintains offices in New York, London, Paris, and Hong Kong and operates a substantial evergreen capital base to sustain support for portfolio companies over extended horizons.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven companies, particularly in life sciences, biotechnology and related technologies. It backs early-stage ventures co-founded by scientists and entrepreneurs, and provides strategic guidance, expertise, and a broad network to translate academic and national-lab innovations into commercial products. The firm operates from Chicago and Seattle and has raised more than $3 billion across ten venture funds and invested in more than 150 companies.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California. It provides capital and operational support to technology and healthcare companies across stages from seed to IPO, with investments spanning software, consumer technology, medical devices, life sciences, AI, energy technology, and related sectors. The firm collaborates with founders on product development, market expansion, and navigating evolving markets, offering domain expertise alongside funding. With a long-standing track record of portfolio companies achieving IPOs and strategic acquisitions, NEA maintains a global footprint and active involvement in the United States, Asia and other regions, supporting companies throughout their growth lifecycle.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It operates a multi-strategy platform spanning venture capital, private equity including buyouts, growth equity, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm backs hundreds of companies worldwide, with a focus on the United States and China, and maintains a track record of portfolio exits through initial public offerings and mergers and acquisitions. Its team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build high-quality healthcare companies and advance patient outcomes. Reported assets under management are approximately six billion dollars.

Khosla Ventures is a California-based venture capital firm founded in 2004 and headquartered in Menlo Park. It provides venture assistance, strategic advice, and capital to entrepreneurs and invests across stages in technology-driven sectors, including artificial intelligence, healthcare, sustainability, digital health, consumer technology, and related deep-tech fields. The firm seeks to back bold ideas with a long-term perspective, often partnering with founders to help scale innovative products and business models. It emphasizes support beyond funding, offering strategic guidance to build companies with durable value and focusing on transformative technologies that address large markets.

Samsara BioCapital is a biotechnology-focused venture capital firm based in Palo Alto, California, established in 2016. The firm concentrates on funding and supporting biotechnology companies and transformative therapeutics across the United States, leveraging multidisciplinary expertise and strategic partnerships to accelerate clinical and commercial breakthroughs. As a registered investment adviser, Samsara BioCapital combines scientific insight with strategic resources to help entrepreneurs advance innovative medicines.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada and Europe. It invests across the healthcare spectrum, including life sciences, biotechnology, pharmaceuticals and medical devices, at early and later stages. The firm blends deep scientific and operating expertise with investment experience to support company building, often applying a hands-on approach to advancing discoveries from academic origins toward commercial therapies and devices. Through its practice and partnerships, Versant has backed portfolio companies that have achieved acquisitions or public listings, underscoring its track record of translating scientific advances into market outcomes.

BioVenture is a China-based healthcare investment firm anchored in Suzhou's bioBAY ecosystem, specializing in early- and growth-stage life sciences companies. Since 2013, it has supported more than 200 portfolio companies across new drug discovery, medical devices, diagnostics, precision medicine and medical services, with a network built on BioBAY that enables post-investment value-add and rapid growth. The company is known for a seasoned investment team, strong industry resources, and world-class scientific advisors, and has backed multiple portfolio companies that have progressed to public listings on major markets. BioVenture emphasizes global reach, robust deal flow, and a commitment to helping portfolio companies scale through strategic guidance and operational support.

Andreessen Horowitz is a venture capital firm founded in 2009 and headquartered in Menlo Park, California. It deploys capital across the full startup lifecycle, from seed to growth, and invests in a broad range of sectors including artificial intelligence, healthcare, consumer technology, fintech, cryptocurrency and blockchain, enterprise software, and infrastructure. The firm offers more than funding, providing an operating network that connects portfolio companies with technical advisors, executive talent, and industry operators to support growth and scale. Through its thought leadership and wide industry coverage, Andreessen Horowitz positions itself as a principal investor in technology-driven companies shaping software-enabled markets.

8VC is a San Francisco based technology investment firm that backs ambitious companies creating lasting economic and societal value by building technology platforms that deliver operational intelligence to complex industries. The firm invests across life sciences, healthcare, AI, financial services, IT infrastructure, logistics, defense, energy, enterprise software and government, and emphasizes a portfolio-support approach to help founders scale transformational technologies with practical operating insights. It pursues industry-wide impact by advancing platform-driven growth and real-world applications that map to business operations. In addition to traditional investments, 8VC runs programs such as the Fellowship and Build to support portfolio companies and create new ventures.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization founded in 1982 and based in Philadelphia that supports the region's technology ecosystem. It provides early-stage and growth capital, along with strategic counsel and connections, to technology companies across information technology, health, and physical sciences sectors in Southeastern Pennsylvania, including Philadelphia and the surrounding counties of Bucks, Delaware, Chester, and Montgomery. The organization partners with universities and other institutions to accelerate the commercialization of scientific discoveries and to foster regional entrepreneurship. Its work aims to create jobs, strengthen communities, and advance innovation by linking entrepreneurs with capital, expertise, and networks.

Legend Capital is a Beijing-based venture capital firm established in 2001 as the investment arm of Legend Holdings. It manages multiple funds with a focus on backing high-growth ventures rooted in China or markets related to China, including early-stage information technology companies and growth-stage opportunities across sectors such as network applications, outsourcing and professional services, infrastructure components, consumer goods, clean technology, healthcare, equipment manufacturing and modern services. As an active investor, Legend Capital provides portfolio companies with strategic resources to support business development and market positioning in China, aiming to create value and maximize returns through hands-on involvement and industry networks.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline. It is a transatlantic life sciences venture capital firm that invests globally in emerging biotechnology, healthcare, and related scientific ventures pursuing innovations with potential to significantly improve medical care. Founded in 1985 and based in Redwood City, California, the firm maintains a presence in major biotech hubs across the United States and London, providing geographic reach and sector expertise to portfolio companies. It employs a back-and-build approach, partnering with founders to translate scientific breakthroughs into new medicines, and has invested around $800 million in more than 180 companies.

Mitsubishi UFJ Capital is the venture capital arm of Mitsubishi UFJ Financial Group, investing in seed and development-stage startups across life sciences, information technology and high-technology sectors with a focus on the Japanese market. Based in Tokyo with offices in Osaka and Nagoya, it pursues a diversified investment program and supports portfolio companies through active collaboration to accelerate growth and readiness for IPOs. By leveraging MUFG’s global network, it seeks strategic partnerships and cross-border opportunities for portfolio companies, including sectors such as healthcare, biotechnology, AI, fintech, SaaS, electronics, and ICT.

Sofinnova Partners is an independent venture capital firm based in Paris, France, founded in 1972, focusing on life sciences across biopharmaceuticals, biotech, medical devices, digital medicine and related sectors. It invests from seed to later stages and often acts as a lead or cornerstone investor, typically engaging early in Round A financings and taking a board seat to work closely with entrepreneurs from formation onward. The firm backs start-ups, early-stage companies, corporate spin-offs and occasional turnaround situations, seeking transformative innovations that can improve patient outcomes and contribute to healthcare and sustainability. Its portfolio approach combines active partnership, hands-on governance and long-term collaboration with founders to advance scientific and clinical progress.

Gaingels is a global venture investment syndicate focused on supporting LGBTQ-founded and led companies and advancing inclusive leadership across stages from early to growth. Founded in 2014 and based in New York, it maintains a portfolio of 130+ companies and about $70 million deployed, and it co-invests with other venture capital partners. Beyond capital, Gaingels assists portfolio firms in recruiting diverse talent for C-suite and board roles and fosters a worldwide community of investors, operators, and entrepreneurs dedicated to positive social change through business.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech, life sciences, human health and planetary health, investing in early-stage and growth-stage companies. It provides capital and strategic guidance to portfolio companies across Europe, North America and beyond, and operates a family of funds totaling several billion euros. The firm backs companies in drug development, biotechnology, medical devices and sustainable technologies, with ESG considerations integrated into its investment approach. Its team spans the Netherlands, Germany and the United States, and the firm has notable investments in Azafaros, VectorY and Genomines.

IMM Investment is a Seoul-based asset manager and private equity/venture capital firm that engages in multi-asset investments across venture capital, growth equity, mezzanine, and infrastructure. The firm targets information technology, healthcare/biotech, manufacturing, and related high-growth sectors, and often takes an active management role to support portfolio companies. With offices in Seoul, Tokyo, and Hong Kong, it serves institutional investors and partners with innovative entrepreneurs through a diversified platform and cross-border strategies.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. Founded in 2009, it operates as a management company that backs companies from early creation to development and expansion, often collaborating with leading academic research institutions and hospitals to translate discoveries into medicines and medical devices. The firm manages funds targeting life sciences, pharmaceuticals, biotechnology, digital health and related technologies, supporting European early-stage and growth-stage ventures through strategic partnerships and long-term value creation.

IDG Capital is a global venture capital and private equity firm founded in 1993 and headquartered in Hong Kong. It operates across multiple markets with a broad international footprint and manages investments in technology, consumer, healthcare, and finance sectors, supporting companies through venture, growth, buyouts, and secondary investments. The firm emphasizes long-term value creation by combining global resources with local market insight to help founders scale, pursue geographic expansion, and form strategic partnerships, with a history of cross-border activity and exits in China and beyond.

Shenzhen Capital Group is a government-backed venture capital firm established in 1999 by the Shenzhen government. It concentrates on cultivating national industries and brands, promoting economic transformation, and supporting enterprises in emerging sectors. The firm invests in SMEs and innovative high-tech companies across information technology, the internet, new media, biopharma, new energy, environmental protection, chemical engineering, new materials, high-end equipment manufacturing, and consumer services, including startups and growth-stage firms. It operates a broad network of funds across 28 provinces, enabling cross-regional capital flows and collaboration among government, industry, and academia to link the Guangdong-Hong Kong-Macao Greater Bay Area with other regions. The approach emphasizes long-horizon value creation, ESG considerations, and aligning financial returns with social impact, contributing to modernization and high-quality development in China.

HBM Healthcare Investments is a Switzerland-based investment firm focused on globally diversified investments in private and public healthcare companies. Founded in 2001 and headquartered in Zug, it concentrates on sectors including human medicine, biotechnology, medical technology and diagnostics, maintaining a portfolio across private holdings, public equities and funds. The company seeks exposure to healthcare growth drivers such as medical innovation, rising access to care and demographic trends, and operates with a global reach to identify opportunities across mature and emerging companies.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

Right Side Capital Management is a San Francisco-based venture capital firm that targets early-stage, capital-efficient technology startups. Using a quantitative, data-driven approach, it makes rapid funding decisions for companies that are pre-product-market fit or early in their development, often with small rounds and modest valuations. The firm emphasizes speed and transparency, typically delivering a yes or no decision within weeks, and it seeks to build ultra-diversified portfolios across many portfolio companies. Beyond capital, it provides substantial post-investment mentorship and operational support, including guidance on sales and marketing and other growth functions, leveraging the founders' decades of tech experience and an expansive network. Investments span the United States and Canada, with activity focused on technology-enabled companies across these markets. Since its founding in 2012, Right Side Capital positions itself as funding startups that are underserved by traditional professional investors, operating like an operating company rather than a conventional VC and aiming to help founders accelerate fundraising and scale their ventures.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Takeda is a leading global biopharmaceutical company headquartered in Japan that researches, develops, manufactures, and markets prescription medicines and nutritional products. Its core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for a large share of revenue. The company maintains a broad geographic footprint with activity in the United States, Europe, Japan, and Canada, supported by an integrated research, development, manufacturing, and commercialization network. Takeda emphasizes innovation to improve patient outcomes through scientific discovery, strategic collaborations, and expanded access to medicines, while upholding strong governance and corporate responsibility.

TCG Crossover is a science-driven healthcare investment firm focused on supporting the development of disruptive medicines. It invests in both private and public companies led by entrepreneurs pursuing better treatment options and maintains a portfolio aimed at advancing innovative pharmaceutical solutions. Based in Palo Alto, California, with investment teams in Palo Alto and New York City, the firm targets investments in the United States and Europe, emphasizing healthcare, digital health, and health technology sectors.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Oak HC/FT is a venture and growth equity investment firm based in Stamford, Connecticut, founded in 2014. It concentrates on healthcare information services and financial services technology, aiming to drive transformation in these sectors. The firm supports portfolio companies with strategic counsel, board-level participation, and access to a broad network of industry leaders to help scale innovative businesses in the United States. Oak HC/FT emphasizes long-term partnerships with founders and collaboration across its sector-focused teams to build growth and value.

Atlas Venture is a biotechnology-focused venture capital firm based in Cambridge, Massachusetts, with a long history dating back to 1980. The firm backs early-stage life sciences companies and technology startups, emphasizing seed-led venture creation and lead investing with board representation to help translate breakthrough science into medicines and medical technologies. Atlas partners with life science entrepreneurs across the United States and Europe, supporting companies in biopharmaceuticals, therapeutics, drug discovery platforms, diagnostics, medical devices, and related biotech innovations. The firm combines venture capital expertise with operational insight to build scalable companies, aiming to advance science from discovery to commercialization. Through its incubator and portfolio approach, Atlas has fostered numerous startups and maintains a focus on personalized medicine and next-generation biotech platforms.

CDH Investments is an international private equity and diversified alternative asset manager founded in 2002 and based in Beijing with an office in Hong Kong. The firm operates a multi-asset platform spanning private equity, venture, growth capital, real assets, credit, mezzanine, public equities and wealth management, with a focus on Greater China and selective cross-border opportunities in Southeast Asia. It targets investments in consumer, technology, new energy and healthcare sectors, among others, and has a track record of large-scale deals and strategic collaborations including the buyout of Shuanghui (WH Group) and related corporate activity. Backed by institutional investors, CDH Investments manages substantial assets and serves a broad set of institutional clients, emphasizing long-term value creation and active portfolio management.

Catalio Capital Management is a New York-based venture capital firm focused on healthcare and biomedical technology. Founded in 2020, the firm invests across the lifecycle of companies in private equity, private credit, and public markets, employing a long-biased, fundamental, bottom-up approach and leveraging structured opportunities and co-investments. It uses a network of scientist-entrepreneurs as venture partners to source deals and provide domain expertise. As of 2025, the firm manages approximately $2 billion in assets with a team of more than 40 staff and around 45 venture partners. Catalio supports portfolio companies across drugs, AI-enabled technologies, and diagnostics, aiming to build category-defining businesses and participating in liquidity events such as IPOs and M&A.

Founded in 1972, Sequoia Capital is a venture capital firm based in Menlo Park, California. It provides capital and strategic guidance to a limited number of companies across the idea to growth stages, emphasizing long-term partnerships. The firm invests globally in software, information technology, internet, mobile, TMT, healthcare, financial services, energy, media, and retail sectors, often supporting companies from early formation through scale. Sequoia collaborates with portfolio leadership to help with product development, market expansion, and company building, drawing on deep operating experience and a focus on enduring value creation.

Merck is a global, research-intensive biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines and vaccines. It pursues therapies across oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology, leveraging data science and artificial intelligence to advance drug development. Its immuno-oncology portfolio, including Keytruda, is a major contributor to sales, and its vaccines business, including Gardasil, targets pediatric diseases. The company emphasizes patient access through assistance programs and sustainability initiatives such as Merck for Mothers. With a long history and a global footprint, Merck focuses on scientific breakthroughs and aims to address unmet medical needs worldwide.

FJ Labs is a New York-based venture capital firm founded in 2015 by Fabrice Grinda. It specializes in marketplaces and consumer-facing startups and is stage-agnostic, making seed to Series A investments with typical checks ranging from 50,000 to 5,000,000. The firm backs founders pursuing network effects and scalable models across consumer internet, e-commerce, fintech, and related sectors, aiming to support transformative growth. Its portfolio includes companies such as Alibaba Group, Beepi, BrightRoll, Betterment, Adore Me, and Earnest, reflecting a broad approach to marketplaces and consumer ventures. FJ Labs emphasizes passion, execution, and tenacity in founders and actively seeks new opportunities to back impactful businesses.

SMBC Venture Capital is the venture capital arm of Sumitomo Mitsui Banking Corporation, focusing on growth capital and buyouts across information technology, life sciences, services, and manufacturing. A long-established domestic VC, it supports portfolio companies by leveraging the SMBC Group network to connect them with large corporations, talent, and experts, while providing stage-appropriate funding and strategic value. The firm pursues growth-oriented investments and seeks to address social issues through its portfolio, backed by a broad network including audit and securities firms and other investors. Since its founding in 2005 in Tokyo (with offices in Osaka), it has backed hundreds of companies, with a track record of more than 400 portfolio companies achieving IPOs, underscoring its ability to create value. SMBC Venture Capital aims to deliver comprehensive support by integrating investment, promotion, and strategy functions, benefiting from the group's global reach.

Gaorong Capital is a Beijing-based venture investment firm that backs early-stage technology companies in Asia-Pacific. Founded around 2013, it focuses on technology sectors including telecommunications, media, life sciences, cosmetics, and other tech, providing strategic resources and global perspectives to portfolio companies through a diverse base of limited partners and industry executives, including sovereign wealth funds, university endowments, pension funds, and leaders from Tencent, Alibaba, Baidu, JD, Xiaomi, Focus Media and VIPShop.

StartUp Health is a private global organization that backs health innovation by investing in a broad network of entrepreneurs and health tech companies. Since 2011, it pursues a 30-year mission to improve health and wellbeing by cultivating a community of Health Transformers and pursuing health moonshots such as Access to Care, Cure Disease, End to Cancer, Women's Health, Mental Health, Longevity, and Pandemic Response. The organization maintains what is described as the world's largest health innovation portfolio, comprising more than 330 companies across six continents and 26 countries, supported by a network of prominent investors and healthcare partners. Rather than a traditional venture firm, StartUp Health emphasizes collaboration among entrepreneurs, decision-makers, clinicians, investors, and funders, offering events, education, and networking to help health innovators at all stages.

Apricot Capital is a venture capital and investment firm focused on the healthcare sector, backing early and growth-stage companies in areas such as biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics. Founded in 2015, the firm operates with a team of more than 20 professionals and consultants who bring experience across life sciences, medicine, finance, and law. The firm is based in Shanghai, China, and seeks to support healthcare ventures through its specialized knowledge and networks.